BioInvent International AB (LTS:0H22) Moat Score: 0/10 (As of Jul. 12, 2026)


LTS:0H22 BioInvent International AB LTS:0H22
42 GF Score
Price kr23.40
GF Value kr50.35
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BioInvent International AB Moat Score?

BioInvent International AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

BioInvent International AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioInvent International AB might have No Moat - No discernible moat.

BioInvent International AB  (LTS:0H22) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioInvent International AB Moat Score Related Terms

LTS:0H22
42GF Score
BioInvent International AB LTS:0H22
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioInvent International AB (LTS:0H22) Overvalued in 2026?

Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued. The current stock price of kr23.40 is trading 53.5% below its estimated GF Value™ of kr50.35. GuruFocus considers BioInvent International AB to be Possible Value Trap.

Key valuation signals for LTS:0H22:

  • Moat Score: 0
  • GF Value™: kr50.35 vs. price of kr23.40 (53.5% below fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the LTS:0H22 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioInvent International AB Business Description

Other Exchanges BINV:SwedenBIX:Germany
Address Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
42GF Score

Get the complete analysis for LTS:0H22

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.40
Price
kr50.35
GF Value